PRESS RELEASE published on 04/06/2023 at 23:00, 3 years 4 months ago MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melan
PRESS RELEASE published on 03/30/2023 at 13:00, 3 years 4 months ago Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
PRESS RELEASE published on 03/24/2023 at 12:30, 3 years 4 months ago Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
PRESS RELEASE published on 03/23/2023 at 12:02, 3 years 4 months ago Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
PRESS RELEASE published on 03/14/2023 at 22:40, 3 years 4 months ago Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
PRESS RELEASE published on 03/10/2023 at 17:00, 3 years 5 months ago Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
PRESS RELEASE published on 02/28/2023 at 13:30, 3 years 5 months ago Moderna to Present at Cowen's 43rd Annual Health Care Conference
PRESS RELEASE published on 02/23/2023 at 13:00, 3 years 5 months ago Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
PRESS RELEASE published on 02/22/2023 at 22:05, 3 years 5 months ago Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela
PRESS RELEASE published on 02/22/2023 at 13:00, 3 years 5 months ago Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
Published on 08/11/2026 at 14:30, 2 hours 21 minutes ago ACCESS Newswire Reports Second Quarter 2026 Results
Published on 08/11/2026 at 14:30, 2 hours 21 minutes ago AIAI Holdings' Constellation Network Launches Dôr Retail Intelligence: Transformational AI-Powered Retail Intelligence
Published on 08/11/2026 at 14:00, 2 hours 51 minutes ago First Canadian Graphite Signs Agreement with Groupe Nipi, in Collaboration with BBA, for its Preliminary Environmental Study at Lac Guéret Sud
Published on 08/11/2026 at 14:00, 2 hours 51 minutes ago First Canadian Graphite conclut une entente avec le Groupe Nipi en collaboration avec la firme BBA pour une étude environnementale préliminaire au Lac Guéret Sud
Published on 08/11/2026 at 13:30, 3 hours 21 minutes ago Nextech3D.ai CEO Evan Gappelberg Purchases 250,000 Shares in Open Market
Published on 08/11/2026 at 15:57, 53 minutes ago Medios Acquires a 74% Majority Stake in Caelo and Strengthens Its German and European Business in Active Pharmaceutical Ingredients and Excipients
Published on 08/10/2026 at 18:00, 22 hours 51 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 22 hours 51 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 23 hours 6 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 1 day 4 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
